DNA methylation in inflammatory bowel disease and beyond

World J Gastroenterol. 2013 Aug 28;19(32):5238-49. doi: 10.3748/wjg.v19.i32.5238.

Abstract

Inflammatory bowel disease (IBD) is a consequence of the complex, dysregulated interplay between genetic predisposition, environmental factors, and microbial composition in the intestine. Despite a great advancement in identifying host-susceptibility genes using genome-wide association studies (GWAS), the majority of IBD cases are still underrepresented. The immediate challenge in post-GWAS era is to identify other causative genetic factors of IBD. DNA methylation has received increasing attention for its mechanistical role in IBD pathogenesis. This stable, yet dynamic DNA modification, can directly affect gene expression that have important implications in IBD development. The alterations in DNA methylation associated with IBD are likely to outset as early as embryogenesis all the way until old-age. In this review, we will discuss the recent advancement in understanding how DNA methylation alterations can contribute to the development of IBD.

Keywords: Colitis; Crohn’s disease; DNA methyltransferase; Epi-therapy; Intestinal inflammation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • DNA Methylation* / drug effects
  • DNA, Bacterial / metabolism
  • Epigenesis, Genetic* / drug effects
  • Gastrointestinal Agents / therapeutic use
  • Genetic Predisposition to Disease
  • Host-Pathogen Interactions
  • Humans
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / genetics*
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / microbiology
  • Intestines / microbiology
  • Phenotype
  • Risk Factors

Substances

  • DNA, Bacterial
  • Gastrointestinal Agents